Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at email@example.com and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
Google continued to reveal pieces of its expansion into life sciences this week, with a typically ambitious plan to map the characteristics of a healthy human the latest project to go public. The initiative is underpinned by Google's standard building blocks: data and computing horsepower.
Researchers have developed a computational cancer model to predict how a drug will perform in humans, VentureBeat reports.
With the European Parliament's summer break causing progress on new General Data Protection Regulations to stop, cancer experts have taken the opportunity to criticize the proposal. Opponents of the changes warn they could make it practically impossible for researchers to access patient data for cancer research.
With IT playing a bigger and bigger role across the R&D process, market research shop Grand View Research has tipped the computational biology market to achieve a compound annual growth rate (CAGR) of 21.1% over the next six years. And that trajectory will result in the value of the sector topping $4.2 billion by 2020.
The psychiatric sector received a big boost this week when the Broad Institute was given $650 million to investigate the genetic causes of mental illnesses such as schizophrenia and bipolar disorder. And the impact of the work is set to extend far beyond Cambridge, with Broad making the data available to researchers around the world.
The rise of electronic health records was heralded as a step toward the merging of patient care and research, a scenario in which data from the day-to-day of healthcare is gathered to inform treatment and drug development. But a study in the United Kingdom suggests that while technology can now facilitate this vision, the path is blocked by another barrier: red tape.
The deal gives Google a partner with healthcare experience to commercialize the glucose-recording contact lens technology it unveiled earlier this year.
While virtual biotechs and the service providers that support them have been around for years, Transcriptic and rival West Coast startups think they can improve the model through automation. And having raised cash from Google's venture unit and struck deals with some elite academic centers, Transcriptic is now rolling out the next phase of its plan.
The FDA is continuing to push ahead with its openFDA initiative, with this week's rollout of an application programming interface (API) for recall data coming a month after its adverse event system went live. And the regulator plans to maintain the pace throughout the rest of the summer.
Codexis strengthened its ties to small-molecule synthesis this week through a deal with GlaxoSmithKline. The agreement will see GSK pay $6 million upfront and more in milestones to license the platform.